Market Leadership Leverage Daicel Chiral Technologies’ global leadership in enantioselective chromatography and its broad portfolio of chiral and achiral stationary phases to win customers in pharma R&D, QC labs, agricultural and food testing, and academic or government labs. Present opportunities to upsell advanced stationary phases, custom method development, and purification services that support regulated drug development and quality control.

Integrated Growth The Arbor Biosciences acquisition in 2018 signals expansion into sequencing and synthetic biology. Cross-sell chromatography solutions to Arbor customers for sample preparation and QC in sequencing workflows, and develop joint offerings that bundle purification media with sequencing or synthetic biology services.

Strategic BD Momentum Leadership changes show a deliberate focus on technology and business development, including a dedicated director for GMP Analytical Services and Pharma Standards. Engage the BD team to co-create targeted campaigns with CROs/CDMOs and pharma customers, emphasizing Daicel's chromatography media as a compliant, scalable solution for GMP workflows.

Mid-market Expansion With revenue in the mid-market range, there is a clear opportunity to expand within mid-size pharma and biotech firms, plus QC labs in pharma, agriculture and food. Propose high-value chiral and achiral stationary phases, method development, and scalable purification solutions, supported by regional distributors and on-site technical expertise.

Global Credibility As a Daicel subsidiary and global market leader, the company gains regulatory credibility and supply reliability. Leverage this to pursue multinational pharma and CROs seeking compliant, globally supported chromatography solutions and services.